S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

MRK Merck and Co Inc

129.22

0.00 (0.00%)

Pre Market

Last Updated: 03:00:00

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Merck Charts.

Merck and Co Inc News

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Monday 29 April 2024 (2 days ago) • Business Wire

U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Thursday 25 April 2024 (6 days ago) • IH Market News

Futures Pointing To Sharply Lower Open On Wall Street
Thursday 25 April 2024 (6 days ago) • IH Market News

Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Thursday 25 April 2024 (6 days ago) • IH Market News

Merck Announces First-Quarter 2024 Financial Results
Thursday 25 April 2024 (6 days ago) • Business Wire

Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H
Friday 19 April 2024 (2 weeks ago) • PR Newswire (Canada)

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Wednesday 10 April 2024 (3 weeks ago) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Thursday 4 April 2024 (4 weeks ago) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Wednesday 3 April 2024 (4 weeks ago) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Monday 1 April 2024 (1 month ago) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Thursday 28 March 2024 (1 month ago) • Business Wire

GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Wednesday 27 March 2024 (1 month ago) • IH Market News

More Merck and Co Inc News Articles

Yuenglings Ice Cream (PK)

Virexit Technologies (PK)

Elite Pharmaceuticals (QB)

BlueFire Equipment (PK)

FuelCell Energy

Canopus Biopharma (PK)

Tonner One World (PK)

Branded Legacy (PK)

Global Developments (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions